Canada: Medical Diagnostic Claims and "Bilski"

In the long awaited decision in Bilski v. Kappos,1 the U.S. Supreme Court has concluded that the machine-or-transformation ("MOT") test is not the sole arbiter of patentable subject matter for "processes" under section 101 of the U.S. Patent Act.2 The decision is expected to have far reaching effects for business methods and other processes, including medical diagnostics.

The court's majority stated that there are four broad categories for patentable subject matter, namely "processes, machines, manufactures, and compositions of matter". The court affirmed the existence of three specific exemptions to 101's broadest principles: laws of nature, physical phenomena, and abstract ideas. The court refused to accept the MOT test, adopted by the Federal Circuit in its Bilski ruling, as the sole test for determining patent eligible subject matter for processes. The Court also refused to establish a different bright-line test. The MOT test is not dead, however. The decision indicated that the "[MOT] test is a useful and important clue, an investigating tool, for determining whether some claimed subject matter are processes".

Calling into question the MOT test is expected to be far reaching, extending beyond the evaluation of business methods, the subject matter at the heart of Bilski's application. Though not strictly a part of the holding in Bilski, some of the majority agreed3 that the MOT test would create uncertainty as to the patentability in several new areas of technology including advanced diagnostic medicine techniques. This reference to diagnostic techniques may be directed to several recent decisions using the MOT test including, Classen Immunotherapies, Inc v. Biogen IDEC et al.4 and Mayo Collaborative Svcs et al. v. Prometheus Labs.5 Importantly, both cases were remanded the day after Bilski to the Federal Circuit for further consideration.

The claims in Classen6 are directed to methods of selecting vaccine regimes and were found to unpatentable by the District Court as "an attempt to patent unpatentable natural phenomenon". This conclusion was affirmed by the Federal Circuit since the methods "are neither 'tied to a particular machine or apparatus', nor do they 'transform[] a particular article into a different state or thing' Bilski".7 The claim in Classen is similar in format to the claim in Laboratory Corp. v. Metabolite Labs. Inc.8 involving a diagnostic method for identifying a vitamin deficiency based on increased levels of homocysteine in blood.9 However, the diagnostic claim in Metabolite, as affirmed by the Supreme Court, earlier was found patentable and determined to not constitute a law of nature.

The format of the claims in Classen and Metabolite, and many diagnostic claims including genetic testing10 (e.g. Association for Molecular Pathology, et al. v. USPTO, et al.11), are similar and involve identifying a biological state,12 using a diagnostic step that identifies a some type of biomarker,13 and correlating the biomarker with the biological state.14 In Myriad, the District court found that a diagnostic method that involves comparing an isolated DNA with a naturally occurring DNA does not satisfy the MOT test, and that the process of extracting DNA in itself is not transformative, but rather a data-gathering step. That court further concluded that an isolated gene sequence is the same as DNA found in the body. While the Myriad decision has recently been appealed, future developments in Classen, and Myriad will be of great significance to determine the application of the MOT test to claims involving diagnostic methods.

In Prometheus, the opposite conclusion to that of Classen was reached. The Federal Circuit applied the MOT test to consider whether claims15 directed to calibrating an appropriate dosage of an autoimmune medication, was patent eligible subject matter under 35 U.S.C. §101. They stated that the "transformation is of the human body following administration of a drug and the various chemical and physical changes of the drugs metabolites that enable their concentrations to be determined". In this method, the drug (a thiopurine) "necessarily under goes a transformation" within the body after administration, and "a process for a chemical or physical transformation of physical objects or substances is patent-eligible subject matter" (emphasis in the original text).

One of the challenges raised in Prometheus was that transformation within the body is a natural processes because "quite literally every transformation of physical matter can be described as occurring according to natural processes and natural law". Interestingly, even though the claims in Prometheus were found to pass the MOT test, this case was also remanded following Bilski, likely as a result of the conclusion that the MOT test is not the sole test.

Applicants and licensees will watch with interest the upcoming decisions in the remanded cases. In the meantime, incorporating diagnostic claims in an application is still an appropriate strategy while the patentablility of this type of claim remains unclear. Where possible, other claim types ought to be included, such as kit claims, or claims that tie the diagnostic process to an apparatus.

Footnotes

1. 08-964, U.S. Supreme Court; "Bilski"

2. 35 U.S.C. §101

3. Slip op. Part II-B-2. pp.8-10

4. 08-1509, U.S. Federal Circuit; "Classen"

5. 09-490; U.S. Federal Circuit; "Prometheus"

6. US 5,723,283; Claim 1 reads:

A method of determining whether an immunization schedule affects the incidence or severity of a chronic immune-mediated disorder in a treatment group of mammals, relative to a control group of mammals, which comprises immunizing mammals in the treatment group of mammals with one or more doses of one or more immunogens, according to said immunization schedule, and comparing the incidence, prevalence, frequency or severity of said chronic immune-mediated disorder or the level of a marker of such a disorder, in the treatment group, with that in the control group.

7. 545 F.3d.at 954

8. 04-607; U.S. Supreme Court; "Metabolite"

9. US 4,940,658. Claim 13 reads:

A method for detecting a deficiency of cobalamin or folate in warm-blooded animals comprising the steps of: assaying a body fluid for an elevated level of total homocysteine; and correlating an elevated level of total homocysteine in said body fluid with a deficiency of cobalamin or folate.

10. US 5,747,282; US 5,837,492; US 5,693,473; US 5,709,999, US 5,710,001; US 5,753,441; US 6,033,857

11. 09- CIV 4515; U.S. District Court, "Myriad"

12. a vitamin deficiency (Metabolite), or a chronic immune-related disorder (Classen)

13. assaying a bodily fluid to detect elevated homocysteine levels (Metabolite), or immunizing mammals with one or more doses of one or more immunogens (Classen)

14. correlating elevated homocysteine with the vitamin deficiency (Metabolite), or comparing the incidence, prevalence, frequency or severity of chronic immunemediated disorders in mammals immunized according to the immunization schedule (Classen).

15. Prometheus was the sole licensee of US 6,355,623 and US 6,680,302; Claim 1 of the '623 patent was cited in the Federal Circuit opinion as being representative: A method of optimizing therapeutic efficacy for treatment of an immune-mediated gastrointestinal disorder, comprising: (a) administering a drug providing 6-thioguanine to a subject having said immune-mediated gastrointestinal disorder; and (b) determining the level of 6-thioguanine in said subject having said immune-mediated gastrointestinal disorder, wherein the level of 6-thioguanine less than about 230 pmol per 8x108 red blood cells indicates a need to increase the amount of said drug subsequently administered to said subject and wherein the level of 6-thioguanine greater than about 400 pmol per 8x108 red blood cells indicates a need to decrease the amount of said drug subsequently administered to said subject.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Events from this Firm
19 Sep 2019, Seminar, Birmingham, UK

Providing GCs, Heads of Legal and senior in-house lawyers with timely, topical and practical legal advice on a variety of topics.

26 Sep 2019, Seminar, London, UK

Providing GCs, Heads of Legal and senior in-house lawyers with timely, topical and practical legal advice on a variety of topics.

8 Oct 2019, Seminar, Birmingham, UK

Supporting the development of paralegals, trainees and lawyers of up to five years' PQE by providing valuable knowledge and guidance together with practical tips.

 
In association with
Related Topics
 
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions